# P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants

> **NCT06079775** · PHASE1 · COMPLETED · sponsor: **Qpex Biopharma, Inc.** · enrollment: 53 (actual)

## Conditions studied

- Bacterial Infections

## Interventions

- **DRUG:** Xeruborbactam Oral Prodrug
- **DRUG:** Ceftibuten
- **DRUG:** Xeruborbactam Oral Prodrug Placebo
- **DRUG:** Ceftibuten Placebo

## Key facts

- **NCT ID:** NCT06079775
- **Lead sponsor:** Qpex Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-30
- **Primary completion:** 2025-01-05
- **Final completion:** 2025-01-05
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2025-12-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06079775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06079775, "P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06079775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*